INTRODUCTION
Thyroid disease is common and yet the management of both thyroid swellings and functional abnormalities remains controversial. Many aspects of thyroid management have not been subjected to randomized controlled clinical trials and most treatment protocols have been based on personal experience or retrospective studies, often conducted in an uncontrolled manner. In spite of this relative lack of controlled data, it is essential that patient selection is undertaken carefully and, if possible, according to clearly defined protocols if we are to see an improvement in outcome and be able to interpret outcome data. This paper addresses the possibility of developing protocols that may be acceptable to a wide range of thyroid clinicians, with the aim that development of such protocols, based on consensus opinion, may facilitate patient management and outcome audit.
There are three main clinical groups of patients presenting with thyroid signs and symptoms for which treatment protocols may be developed: * Patients presenting with diffuse or multinodular goitre * Patients presenting with a solitary or dominant nodules * Patients presenting with thyrotoxicosis.
PATIENTS PRESENTING WITH DIFFUSE OR MULTINODULAR GOITRE
As with all conditions, an accurate diagnosis is dependent upon an adequate history, clinical examination and relevant investigations. The functional investigations routinely available consist of T4 (T3 when specifically requested), thyroid stimulating hormones (TSH) and thyroid antibodies. Serum calcitonin should be requested whenever there is any suspicion of medullary carcinoma and serum calcium should be assessed before any thyroid surgery is undertaken. Clinical examination should indicate the nature of any thyroid swelling as to whether it is multinodular, diffuse or a solitary nodule, with confirmation by ultrasound scanning when required (Figure 1 ). For the diffuse or multinodular goitre that is asymptomatic and not providing cosmetic embarrassment, no action is required as long as any risk of Royal Hallamshire Hospital, Sheffield, UK malignancy can be excluded. The role of thyroxine therapy to suppress TSH in an attempt to reduce the size of goitres remains controversial. Certain studies have suggested it may be of valuel 2, although others have found it unhelpful3. Clinical experience suggests that, although TSH suppression may be helpful in the early stages of development of multinodular goitre, it is unsuccessful in decreasing the size of established nodules, which is usually when it is most required. The role of radioactive iodine in this situation is also unproven and controversial and, although some support its use4, it should be used with caution and care. The disadvantages of radioactive iodine include the high incidence of subsequent hypothyroidism as well as its relative contraindication in retrosternal goitres because of the initial reactive swelling of the thyroid which can exacerbate any compression symptoms.
For those patients with symptomatic goitres, giving rise to pressure symptoms, discomfort, recurrent bleeds into degenerate areas or cosmetic problems, surgery should be offered in the form of bilateral partial, near or total thyroidectomy ( Figure 2 ). The fact that thyroxine is often ineffective in presenting recurrence of thyroid nodules has led some workers to advocate near-total thyroidectomy for multinodular goitres5. This may be a satisfactory policy for very experienced thyroid surgeons but the lower rate of recurrent laryngeal nerve damage and parathyroid insufficiency said to be associated with subtotal thyroidectomy makes this the procedure of choice for many surgeons. For those patients undergoing surgery for cosmetic reasons only, the risk of keloid formation should be discussed, especially in those most at risk, for example adolescents and those of black or oriental origin.
Retrosternal thyroid swellings should be carefully assessed for any degree of tracheal compression and functional embarrassment by computerized tomography (CT) scanning which is of particular value for assessing objectively the degree of tracheal compression or displacement which can be accurately measured6. Thoracic inlet X-rays are notoriously misleading as to true tracheal compression. Functional impairment may be assessed by peak flow measurements but this does not Figure 2 ).
MANAGEMENT OF NODULES WITH MALIGNANT OR SUSPICIOUS CYTOLOGY
In all patients with malignant or suspicious cytology, a strategy of management needs to be adopted that reflects the associated risk factors, the aggressiveness of the disease and its prognosis. Therefore, decisions as to the best operative procedure finally adopted should take into consideration the biological characteristics of the neoplasm, including its aggressiveness, its potential for local recurrence, its potential for distant metastasis and the operative morbidity of the chosen procedure. 20 years have an almost normal life expectancy. Size is also important with tumours < 1.5 cm having a mortality of 0.8% which rises to 12.6% for those >4cm.
Based on the above information a suggested strategy for management of differentiated carcinoma is presented in Figure 3 . Total lobectomy should be performed initially and this may well be adequate for papillary carcinomas < 1.5 cm that are confined to one lobe without metastatic involvement of ipsilateral lymph nodes, and follicular carcinomas confined to one lobe with minimal capsular invasion and absent metastatic disease. Thyroxine should be given to suppress TSH drive with the aim of keeping the value in serum < 0. 03 U/ L.
Total thyroidectomy should be performed in patients with papillary carcinomas that are > 1. 5 A pre-operative diagnosis of medullary carcinoma should be possible and, if suspected, then serum calcitonin and FNAC should be performed. Medullary carcinoma may occur sporadically or be part of a multiple endocrine neoplasia syndrome, either MEN2a25 or MEN2b26. Therefore, a careful family history should be taken, blood taken for genetic markers and both phaeochromocytoma and hyperparathyroidism excluded by an assessment of blood pressure, 24h urinary catecholamines, serum calcium and parathormone levels. A CT scan of the neck, thyroid and the adrenals should be performed. As medullary carcinoma is usually multifocal and bilateral, treatment consists of total thyroidectomy with or without neck dissection depending on any evidence of lymph node metastases. If the disease is extensive, then surgery should be followed by external beam irradiation. Post-operative follow-up consists of regular assessment of calcitonin levels. When these remain low, then annual examination and calcitonin levels are all that is required. However, calcitonin levels often do not fall to normal levels. In these cases it is important to assess the extent of any residual disease by means of a CT scan, bone scan and dimercaptosuccinic acid whole body scan. Where surgical resection is feasible, this should be undertaken but often this is not a practical treatment option. A diagnostic 131 I-MIBG scan (131 meta-iodobenzylguanidine) may be performed as it has been shown to be taken up by medullary carcinomas as well as phaeochromocytomas27. However, the uptake is less than one-hundredth of that of phaeochromocytoma cell lines28 and, therefore, its role in this situation is limited. Where a diagnostic 131 I-MIBG scan is positive, a therapeutic dose of irradiation may be given. Often a patient may live with their medullary carcinoma metastases, almost in symbiosis, for many years with little in the way of symptoms. However, if the disease is progressive, then chemotherapy with or without external irradiation may be administered, but the results are poor.
Anaplastic carcinoma
Most patients with anaplastic carcinomas give a history of a pre-existing goitre with recent sudden progressive enlargement. Pressure symptoms may develop with dyspnoea, dysphagia and voice change. The gland is usually hard, irregular and fixed. The diagnosis may be achieved by FNAC and staging assessed by CT scanning of the neck, mediastinum, lungs and liver. In the rare situations in which an anaplastic tumour is localized, a total thyroidectomy may be indicated but is seldom achievable. In most cases, open biopsy is all that is possible and a tracheostomy is performed only if essential. Surgery is followed by radiotherapy, with chemotherapy for widespread symptomatic disease. In spite of all endeavours, the prognosis is dismal and has hardly changed over the last 20 years, with less than 5% of patients surviving 3 years29.
PATIENTS PRESENTING WITH THYROTOXICOSIS
Once diagnosed, the initial aim in the management of thyrotoxicosis is to render the patient clinically and biochemically euthyroid. A prolonged course of thionamides, either carbimazole or propylthiouracil, should be used in patients presenting with their first episode of Graves' thyrotoxicosis in the hope that long term remission will be achieved30. Carbimazole is usually chosen as the first line of treatment, although propylthiouracil is preferred in pregnancy3l or breast feeding32. The recommended Thyrotoxicosis duration of treatment is between 6 months and 2 years and any longer course of treatment is unlikely to achieve a greater remission rate. Serious side-effects such as agranulocytosis, hepatitis and lupus-like syndromes are rare but remain absolute contraindications to the use of thionamides. More common but mild side-effects such as pruritus and rashes may settle with continuing treatment but, if they persist, then a change from carbimazole to propylthiouracil may be required. Beta adrenergic blockade should be considered in those patients with severe thyrotoxicosis but should be avoided in asthma sufferers. Those agents that can be given once daily such as nadalol or atenolol are associated with improved compliance.
Once the patient has been rendered euthyroid, subsequent management will depend on the natural history of the condition, the age and sex of the patient and the underlying pathology. In those patients in whom long-term remission occurs, no further action is required other than regular monitoring of thyroid function. In those patients in whom recurrent thyrotoxicosis occurs, the initial management is to render them euthyroid once more and then to consider the use of radioiodine or surgery. Radioiodine is suitable for nearly all forms of thyrotoxicosis, especially in elderly patients. However, it is contraindicated in children, pregnant women and those who are breast feeding. A further relative contraindication is women who have young children as they have to avoid close contact with them, and women of childbearing age are advised to wait at least 4 months after radioiodine before becoming pregnant33. It is for this reason that many prefer surgery in women under the age of 40 years.
Surgery for thyrotoxicosis is safe in experienced hands and is indicated in patients with a large goitre, failed medical management due to either poor compliance or sideeffects of medication, patient preference or toxic nodular goitre (Figure 4) operation for a solitary hot nodule as a simple lobectomy cures the patient with little risk of hypothyroidism. Other workers view this as being the ideal condition for radioiodine, although there is a slight risk of hypothyroidism if the radioiodine is taken up by the normal thyroid tissue as well as the hot nodule. Surgery is also an option in pregnancy when it should preferably be performed in the second trimester. All patients being prepared for surgery should be clinically and biochemically euthyroid and in most centres will have a pre-operative cord check. This is essential in all re-operations. A subtotal thyroidectomy should be performed endeavouring to leave a remnant of about 5 g as the aim is to maintain the patient's euthyroid status. In spite of this, permanent hypothyroidism occurs in 50/o-40% of patients with Graves' disease and the prevalence increases with time34. This is more likely to occur in patients with a small gland and those thyroids in which a significant lymphocytic infiltration is seen on histological examination of the resected specimen. Complications should be infrequent but include haemorrhage, wound infection, recurrent laryngeal and external branch of superior laryngeal nerve neuropraxia or damage and transient or permanent hypocalcaemia, the latter occurring in about 2% of patients. 35 . Recurrent thyrotoxicosis occurs in 10/6-3% of patients within the first year and, thereafter, about 1% a year36. Recurrent hyperthyroidism should be treated with radioiodine.
CONCLUSION
All patients with thyroid disease should have access to units with expertise in treating thyroid disorders. Annual assessment of TSH levels are required after any treatment, whether it be medication, radioiodine or surgery, to ensure compliance and avoid hypothyroidism as well as to pick up any potential recurrence of hyperthyroidism. In those patients in whom there is no potential for malignancy, such follow-up may be organized by means ofan endocrine computerized follow-up service but, for those with thyroid carcinoma, follow-up by means of thyroglobulin, TSH and scanning should be accompanied by regular clinical examination.
Treatment protocols as outlined above are presented as an attempt to provide guidelines as to management for both purchasers and providers in an environment of increasing subspecialization. They are, however, not meant to be viewed as rigid lines of management as many thyroid clinicians' treatment regimens may vary to a degree from these proposals. However, the use of such management protocols will provide a high standard of care for patients with thyroid disease and will allow more meaningful audit of outcomes.
